Efforts in metastasis research have centered on the phenotypic and genetic differences between primary site and metastatic site tumors. However, genes that may be used as molecular markers of metastasis in circulating tumor cells remain unidentified. Genes regulating the dissemination and survival of solid tumor cells in the blood, as well as their adaptation to new environments, could be candidates for unique metastatic tumor markers. Differential display (DD) was conducted to compare the blood of tumor-free individuals with the blood of patients with lung, breast, and colon cancers. Twenty-one up-expressed genes in the tumor patient blood samples but
Introduction
Cancer recurrence and metastasis continue to pose major problems in clinical management (1) . Advances in diagnostic techniques and technology may allow cancer detection at earlier stages, when the tumor burden is smaller and potentially more curable. The relationship between circulating tumor cells and the development of secondary disease is not fully understood and a Correspondence and reprint requests to: Dr. Marcia V. Fournier, Cancer Biology Division, Dana-Farber Cancer Institute, Boston, MA 02115, U.S.A. Phone: 617-632-4683; Fax: 617-632-4680; E-mail: fournier@mbcrr.harvard.edu none in the tumor-free donor blood samples were identified. Nine of these samples were isolated, amplified, and directly sequenced. A gene AB-I homologous to a Bcl-2 family member, which might function as an apoptosis inhibitor, was identified. The overexpression of an apoptosis inhibitor in blood from patients with metastatic tumors might be correlated with the capability of solid tumor cells to survive in peripheral blood. This is the first demonstration of the usefulness of comparing control and patient blood samples by DD to find novel potential genetic markers identifying metastasis in the blood. method to detect small numbers of such cells may provide a tool with which to evaluate their role in the disease process. However, very little is known about the molecular mechanism that regulates circulating tumor cells' survival and metastasis. Genes regulating the dissemination and survival of solid tumor cells in the blood, as well as their adaptation to new environments, could be candidates for unique metastatic tumor markers.
Systemic spread of tumor cells in peripheral blood is an essential step for hematogenous metastasis (2) . The vast majority of tumor cells that enter the circulation are rapidly elim-inated by factors such as blood turbulence (3), natural killer cells (4) , and macrophages (5). Nitric oxide secretion by activated macrophages and endothelial cells is a major cytotoxic mediator responsible for the destruction of tumor cells passing through capillary beds (6) . In addition, activation of apoptosis also contributes to eliminate metastatic cells (7, 8) . In contrast, fibrin deposits, platelet aggregation, and adhesion around the tumor emboli may protect circulating cells from mechanical trauma, facilitate their arrest in capillary beds, and protect tumor emboli from destruction by host immunity (9) .
To find novel genetic markers for solid tumor cells circulating in blood, differential display (DD) (10) was conducted to compare RNA isolated from the blood of tumor-free individuals with RNA from the blood of patients with lung, breast, and colon cancers.
Materials and Methods
Patients' Samples Eleven blood samples from patients with histologically documented nonhematological cancer, with either localized or metastatic disease, were analyzed. All lung cancer blood samples analyzed in this study were collected before anti-tumor chemotherapy treatment or surgery. For To begin identifying metastatic genes, the RNA of two individual control donor blood samples, representing the greatest variation between individuals, and up to five metastatic cancer patient blood samples were compared by DD. As potential markers, we considered RNA up-regulated in at least two patient blood samples and low or absent in normal blood samples. Differentially expressed cDNA fragments of interest were isolated and reamplified by PCR using DD primer (14) . A total of 15 up-regulated bands identified by this strategy were isolated. Five of these were overexpressed in blood samples from lung and breast cancer and were considered candidates for general molecular markers for tumor dissemination ( Table 2) . One of the bands was also detected in the blood sample of a colon cancer case. Figure 2A shows a comparison of blood from tumor-free donors with that from two metastatic lung cancer patients, P1 and P2, respectively. A cDNA fragment differentially expressed in patient blood denominated AB-1 (Apoptosis in Blood-1) that bears 95% homology with a gene similar to the human Al protein in a database of expressed sequences tags (EST) was identified (GenBank ID AA282294). Human Al protein is a member of the bcl-2 family, described as an apoptotic suppressor (16) . The identification of an apoptosis inhibitor homologue gene in blood from patients with metastatic tumors might be correlated with the capability of solid tumor cells to survive in peripheral blood.
In an attempt to identify tumor-specific metastatic markers, we next analyzed a pool containing RNA from blood of four individual normal donors (CP) compared with pools of RNA from blood of three metastatic lung cancer patients (LP) and two metastatic breast cancer patients (BP) (Fig. 2B) . The comparison of these samples by DD identified one lung-specific gene (LI), two breast-specific genes (BI and B2), and one general gene (GP1). The comparison of the control donor pool (CP) with a pool of metastatic tumor blood RNA consisting of LP, BP, and one metastatic colon cancer blood sample by DD generated very few differences in cDNA pattern and was not a useful strategy for investigation of general molecular markers (data not shown). Figure 3A shows that AB-1 was not expressed in three tumor-free donor blood samples. AB-1 was up-regulated in 720/o of cancer patient blood samples tested (Fig. 3B ). More than 10-fold overexpression was observed in four out of eight metastatic cancer blood samples (Fig. 3B, lanes 5, 7, 12, and 14) . Three of them were cases of small-cell lung can- (18) . However, human Al is not restricted to endothelial cells and has a widespread tissue distribution, including leukocytes (16) . GRS expression in normal human tissues is largely restricted to the hematopoietic compartment as well as in hematopoietic malignancies and melanoma cell lines (19) . Our data support that AB-1, in contrast with its homologues Al and GRS, is not expressed in normal leukocytes and is present in blood samples from solid-tumor patients.
Efforts in metastasis research have centered on the phenotypic and genetic differences between primary site and metastatic site tumors. They focus on differences in angiogenesis, signal transduction pathways, cell communication, migration, and adhesion. However, genes that could be used as molecular markers of tumor dissemination and metastasis, and the biological role of these genes in circulating tumor cells, remain unidentified (20) . This is the first demonstration of the usefulness of comparing control and patient blood samples by DD to find novel genetic markers for metastasis. Genes aiding metastatic tumor adaptation to new environments and survival in the blood, such as the potential apoptotic inhibitor AB-1, need to be further characterized for clinical use.
